Maxygen

Maxygen board to dissolve, liquidate company

Wednesday, June 5, 2013

The board of biopharmaceutical company Maxygen has approved the liquidation and dissolution of the company, subject to shareholder approval, and plans to distribute all available cash to its shareholders after making reasonable provision for known and potential liabilities and other obligations of the company. Maxygen currently estimates the initial liquidating distribution to stockholders will be between $68.2 million and $69.6 million, or $2.45 to $2.50 per share.

[Read More]

Altravax awarded $1.2M to advance dengue vaccine and hep B therapeutic

Friday, January 11, 2013

Altravax, a privately held biopharmaceutical company based in Fargo, N.D., has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH’s National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax’s two lead commercial programs.

[Read More]

DART Therapeutics appoints executive team

Friday, September 14, 2012

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

[Read More]